Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PTC Therapeutics Inc (NASDAQ: PTCT) closed the day trading at $39.36 up 0.33% from the previous closing price of $39.23. In other words, the price has increased by $0.33 from its previous closing price. On the day, 0.82 million shares were traded. PTCT stock price reached its highest trading level at $40.06 during the session, while it also had its lowest trading level at $38.71.
Ratios:
For a better understanding of PTCT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.04 and its Current Ratio is at 2.10.
On September 04, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $44.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 16 ’24 when Gravier Pierre sold 2,269 shares for $34.02 per share. The transaction valued at 77,200 led to the insider holds 53,531 shares of the business.
ZELDIS JEROME B sold 20,000 shares of PTCT for $764,800 on May 22 ’24. The Director now owns 14,500 shares after completing the transaction at $38.24 per share. On May 07 ’24, another insider, Golden Lee Scott, who serves as the EVP & CHIEF MEDICAL OFFICER of the company, sold 175 shares for $32.82 each. As a result, the insider received 5,744 and left with 59,813 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 3035644160 and an Enterprise Value of 4484490240. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.37. Its current Enterprise Value per Revenue stands at 4.979 whereas that against EBITDA is 205.259.
Stock Price History:
Over the past 52 weeks, PTCT has reached a high of $46.98, while it has fallen to a 52-week low of $20.50. The 50-Day Moving Average of the stock is 1.66%, while the 200-Day Moving Average is calculated to be 18.02%.
Shares Statistics:
Over the past 3-months, PTCT traded about 698.84K shares per day on average, while over the past 10 days, PTCT traded about 780770 shares per day. A total of 75.71M shares are outstanding, with a floating share count of 74.50M. Insiders hold about 3.40% of the company’s shares, while institutions hold 101.74% stake in the company. Shares short for PTCT as of 1730332800 were 4886780 with a Short Ratio of 6.99, compared to 1727654400 on 4272376. Therefore, it implies a Short% of Shares Outstanding of 4886780 and a Short% of Float of 9.8900005.
Earnings Estimates
PTC Therapeutics Inc (PTCT) is currently under the scrutiny of 4.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.29, with high estimates of $0.29 and low estimates of $0.29.
Analysts are recommending an EPS of between -$3.72 and -$4.69 for the fiscal current year, implying an average EPS of -$4.29. EPS for the following year is -$3.75, with 5.0 analysts recommending between $0.02 and -$7.0.
Revenue Estimates
11 analysts predict $190.47M in revenue for the current quarter. It ranges from a high estimate of $220.3M to a low estimate of $172.77M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $307.06MFor the next quarter, 11 analysts are estimating revenue of $161.02M. There is a high estimate of $228.6M for the next quarter, whereas the lowest estimate is $118.7M.
A total of 14 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $814M, while the lowest revenue estimate was $764.7M, resulting in an average revenue estimate of $783.74M. In the same quarter a year ago, actual revenue was $937.82MBased on 14 analysts’ estimates, the company’s revenue will be $721.46M in the next fiscal year. The high estimate is $882M and the low estimate is $570.8M.
